Asset profile

Depemokimab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved — Asthma

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Chronic Obstructive Pulmonary Disease · Phase 3

How the evidence outlook works ↗

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2028 (1)
January 2028 (1)
Phase 3AsthmaRecruiting
Est. primary completion 2028-01-05 · NCT06979323 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (4)
March 2029 (1)
Phase 3AsthmaNot yet recruiting
Est. primary completion 2029-03-19 · NCT07671001 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2029 (1)
Phase 3Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2029-04-30 · NCT07177339 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2029 (2)
Phase 3Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2029-08-20 · NCT06959095 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2029-08-21 · NCT06961214 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)
September 2030 (1)
Phase 3AsthmaRecruiting
Est. primary completion 2030-09-23 · NCT07456033 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.